|
|
||||||||
J Thorac Cardiovasc Surg 2000;119:857
© 2000 The American Association for Thoracic Surgery
LETTERS TO THE EDITOR |
Department of Cardiothoracic Surgery, Hammersmith Hospital, Du Cane Rd, East Acton, National Heart and Lung Institute, Imperial College of Science, London W12 0NN, United Kingdom
To the Editor:
Argenziano and associates,
1 in their article on management of vasodilatory shock after cardiac surgery, provide an excellent study of enormous clinical importance. Identification of low ejection fraction and angiotensin-converting enzyme (ACE) inhibitors as risk factors for vasodilatory shock after cardiopulmonary bypass (CPB) confirms the initial analysis of 2729 patients undergoing CPB in our center.
However, the study raises a number of important issues that were not mentioned:
While discussing the mechanisms for arginine vasopressin deficiency, which may be multifactorial, the authors failed to mention that angiotensin II decreases arginine vasopressin release from the neurohypophysis.
2 This implies that the newer selective angiotensin II inhibitors like losartan may also cause vasodilatory shock.
The majority of patients undergoing routine CPB, regardless of left ventricular function, have no sequelae if the ACE inhibitor is withheld on the morning of the operation. Withholding the ACE inhibitor also may decrease the chance of renal complications via the reduced efferent arterial tone caused by ACE inhibitors, which reduces glomerular filtration rate during CPB.
3 Obviously, withholding the ACE inhibitor is not appropriate in patients awaiting cardiac transplantation or left ventricular assist device implantation, but the ACE inhibitor could be changed to a short-acting one from the long-acting one that most patients receive.
Amiodarone, which is a noncompetitive
-blocker and ß-blocker, is commonly co-prescribed with ACE inhibitors in patients with end-stage cardiac failure before heart transplantation.
4 Amiodarone has been shown to act synergistically with ACE inhibitors in causing vasodilatory shock via a two-hit mechanism.
5 Unfortunately no mention was made of this.
Finally, nicorandil, a new potassium channel opener used in the treatment of angina, in our experience, has been associated with decreased systemic vascular resistance and increased need for vasoconstrictor treatment.
6 This seems to be especially common when patients have taken a 10-mg dose within 12 hours of CPB.
12/8/105207 doi:10.1067/mtc.2000.105207
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |